Livsayis™ (cemdisiran) Approved by the FDA as First and Only siRNA Therapy in Generalized Myasthenia Gravis and Only Treatment with Four-Times-a-Year Subcutaneous Dosing
Approval based on Phase 3 NIMBLE results demonstrating rapid, deep and sustained disease control that is maintained throughout three-month dosing intervals
Approval based on Phase 3 NIMBLE results demonstrating rapid, deep and sustained disease control that is maintained throughout three-month dosing intervals
De nouveaux tableaux de bord et une vérification des documents validée par des experts offrent aux acheteurs une visibilité accrue sur les performances des fournisseurs, la conformité et la traçabilité jusqu’à l’origine De nouveaux tableaux de bord et une vérification des documents validée par des experts offrent aux acheteurs une visibilité accrue sur les performances… ...
Success Knocks Recognition Highlights CallTower's Global Growth and Leadership Across UCaaS, CCaaS, Customer Experience, and AI-Powered Communications Success Knocks Recognition Highlights CallTower's Global Growth and Leadership Across UCaaS, CCaaS, Customer Experience, and AI-Powered Communications ...